Pulmonary aspergillus 1 and rhizopus 2 infections are potentially lethal in immunocompromised patients. Amphotericin B has been the therapy of choice for these infections, but is hampered by poor success rates and substantial side effects. 1, 2 Voriconazole and caspofungin are two new broad-spectrum antifungal agents. Although reports of their efficacy in vivo are very promising, 3, 4 there are limited clinical data on potential synergy between these two agents. There are no data on the use of these agents in combination with amphotericin.
A 51-year-old woman who had undergone a conventional-intensity allogeneic blood stem cell transplant for mantle cell lymphoma from her HLA-identical brother presented with productive cough and fever. She was receiving tacrolimus 2 mg daily and prednisone 15 mg daily for treatment of limited chronic graft-versus-host disease (GVHD) involving the skin, liver and oral mucosa. Antimicrobial prophylaxis comprised of levofloxacin, itraconazole and valacyclovir. The total leukocyte count was 1.6 Â 10 9 /l with absolute neutrophil and lymphocyte counts of 1.2 Â 10 9 and 0.3 Â 10 9 /l, respectively. There was profound hypogammaglobulinemia with IgG 43, IgM 88 and IgA o7 mg/dl. Aminotransferases were marginally elevated (AST 91 and ALT 101) due to GVHD. Kidney function was normal.
She was tachypneic at rest. Chest X-ray revealed bilateral patchy infiltrates, and chest CT scan showed extensive bilateral consolidation. The patient was empirically started on caspofungin (70 mg on day 1, and then 50 mg daily) on admission. Bronchoscopy revealed edematous, inflamed mucosa covered with whitish cheesy material. The bronchial lavage showed fungal hyphae microscopically. Liposomal amphotericin B (LAB) (AmBisome) was added at the dose of 5 mg/kg because of this.
Culture yielded a heavy growth of Rhizopus species and Aspergillus niger ( Figure 1 ). In spite of being on the combination for 4 days, the patient continued to deteriorate and her oxygen requirements increased. In view of the worsening status, voriconazole was added at a dose of 300 mg twice daily and the amphotericin preparation was switched to amphotericin B lipid complex (ABLC) (Abelcet) at a dose of 5 mg/kg. Over the next 4 days, the patient's respiratory status stabilized and then started improving dramatically. No adverse effects were seen.
She was discharged after 10 days of combination therapy when the chest CT scan showed remarkable improvement. Prednisone was reduced to 5 mg daily. A chest CT scan done 3 months after combination therapy was started, showed complete resolution of all infiltrates (Figure 2) . The patient had no reactions to ABLC in the hospital and at home for several weeks. A few weeks after discharge, ABLC was changed to LAB because of infusional reactions at home. However, LAB was discontinued because of elevation in bilirubin and transaminases. Caspofungin was also stopped at the same time. In all, triple therapy was continued for 14 weeks after discharge. The patient is now on voriconazole alone as fungal prophylaxis, and on a low dose of prednisone for chronic GVHD, with no evidence of a systemic fungal infection.
Invasive pulmonary infections with fungi such as Aspergillus spp. are a major source of morbidity and mortality after allogeneic HSCT. However, newer amphotericin a b Figure 1 Rhizopus (a) and Aspergillus (b) grown in culture from bronchoalveolar lavage fluid (microphotographs at Â 10).
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www.nature.com/bmt preparations have improved the outcome of therapy in aspergillosis. 5, 6 The outcome of zygomycosis therapy still remains disappointing with a high mortality in immunocompromised patients. 2 Apart from progression of the infection on LAB, another factor prompted the change from LAB to ABLC. ABLC is associated with achievement of much higher concentrations of amphotericin in lung tissues 5, 7 which may perhaps increase the chance of success. Voriconazole was added as a third agent because the clinical situation was perceived to be exceedingly grim. Voriconazole has been found to be synergistic with terbinafine in a proportion of zygomycetes strains in vitro.
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In vitro susceptibility testing results (Table 1) were incomplete because neither the triple combination nor the combination of amphotericin and voriconazole were tested. It could certainly be argued, based on the susceptibility testing, that ABLC alone was responsible for clearance of rhizopus, and caspofungin mainly responsible for clearance of aspergillus. However, the rapidity of improvement while on immunosuppression in a dismal clinical situation suggests that the triple combination probably played a significant role.
Clearly, such a combination cannot be considered appropriate until more data are available. However, based on our observation, we feel that the triple combination of ABLC, caspofungin and voriconazole may be an option worth exploring in patients with pulmonary fungal infections who do not appear to be improving on more standard therapy.
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